Author:
Lasek Witold,Jakóbisiak Marek
Publisher
Springer International Publishing
Reference130 articles.
1. Algazi A, Tsail KK, Takamura KT, Chen L, Twitty C, Dwyer M, Greaney S, Diep TT, Pierce RH, Le MH et al (2016) Priming response to anti-PD1/PDL1 blockade with intratumoral electroporation of plasmid IL-12 in advanced melanoma. http://oncosec.com/wp-content/uploads/2015/09/AACR-Presentation-Algazi-04192016.pdf
2. Ardolino M, Azimi CS, Ianello A, Trevino TN, Horan L, Zhang L, Deng W, Ring AM, Fischer S, Garcia KC et al (2014) Cytokine therapy reverses NK cell anergy in MHC-deficient tumors. J Clin Invest 124:4781–4794. doi: 10.1172/JCI74337
3. Basak GW, Zapala L, Wysocki PJ, Mackiewicz A, Jakóbisiak M, Lasek W (2008) Interleukin 15 augments antitumor activity of cytokine gene-modified melanoma vaccines in a murine model. Oncol Rep 19:1173–1179. doi: 10.3892/or.19.5.1173
4. Basile LA, Ellefson D, Gluzman-Poltorak Z, Junes-Gil K, Mar V, Mendonca S, Miller JD, Tom J, Trinh A, Gallaher TK (2012) HemaMax, a recombinant human interleukin-12, is a potent mitigator of acute radiation injury in mice and non-human primates. PLoS ONE 7:e30434. doi: 10.1371/journal.pone.0030434
5. Bekaii-Saab TS, Roda JM, Guenterberg KD, Ramaswamy B, Young DC, Ferketich AK, Lamb TA, Grever MR, Shapiro CL, Carson WE 3rd (2009) A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies. Mol Cancer Ther 8(11):2983–2991. doi: 10.1158/1535-7163.MCT-09-0820